Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.4403 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0028 | 0.2561 | 0.2561 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0028 | 0.2561 | 0.2561 |
Brugia malayi | hypothetical protein | 0.0038 | 0.4403 | 0.4403 |
Loa Loa (eye worm) | TAR-binding protein | 0.0066 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.4403 | 0.5 |
Brugia malayi | intermediate filament protein | 0.0028 | 0.2561 | 0.2561 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0066 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.246 | 0.246 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0066 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0066 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.2561 | 0.2561 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.4403 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0038 | 0.4403 | 0.2477 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.4403 | 0.2477 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0038 | 0.4403 | 0.2477 |
Onchocerca volvulus | 0.0028 | 0.2561 | 0.5 | |
Onchocerca volvulus | 0.0028 | 0.2561 | 0.5 | |
Echinococcus granulosus | tar DNA binding protein | 0.0066 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0028 | 0.2561 | 0.2561 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.4403 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0066 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 1 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0038 | 0.4403 | 0.2477 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0066 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibitory potency (binding) | = 0.17 | Ratio of Km(ADP)/Ki or Km for rat kidney pyruvate kinase (PK-K) | ChEMBL. | 7143354 |
Inhibitory potency (binding) | = 0.19 | Ratio of Km(ADP)/Ki or Km for rat muscle pyruvate kinase | ChEMBL. | 7143354 |
Inhibitory potency (binding) | = 0.23 | Ratio of Km(ADP)/Ki or Km for rat liver pyruvate kinase | ChEMBL. | 7143354 |
Km (binding) | = 1.3 mM | Michaelis-Menton constant for inhibition of pyruvate kinase obtained from rat liver (PK-L) was determined using ADP as competitive inhibitor | ChEMBL. | 7143354 |
Km (binding) | = 2.7 mM | Michaelis-Menton constant for inhibition of pyruvate kinase obtained from rat muscle (PK-M) was determined using ADP as competitive inhibitor | ChEMBL. | 7143354 |
Km (binding) | = 2.9 mM | Michaelis-Menton constant for inhibition of rat kidney pyruvate kinase (PK-K) | ChEMBL. | 7143354 |
Relative inhibitory potency (binding) | = 0.74 | Relative inhibitory potency as ratio of kidney and liver pyruvate kinases | ChEMBL. | 7143354 |
Relative inhibitory potency (binding) | = 0.83 | Relative inhibitory potency as ratio of muscle and liver pyruvate kinases | ChEMBL. | 7143354 |
Relative Vmax (binding) | = 15 | Relative half maximal velocity of Pyruvate kinase and Phosphoenolpyruvate | ChEMBL. | 7143354 |
Relative Vmax (binding) | = 15 | Relative half maximal velocity of Pyruvate kinase to Phosphoenolpyruvate was determined | ChEMBL. | 7143354 |
Relative Vmax (binding) | = 26 | Relative half maximal velocity of Pyruvate kinase and Phosphoenolpyruvate | ChEMBL. | 7143354 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.